AU2007236269B2 - Treatment of multiple sclerosis and/or rheumatoid arthritis - Google Patents

Treatment of multiple sclerosis and/or rheumatoid arthritis Download PDF

Info

Publication number
AU2007236269B2
AU2007236269B2 AU2007236269A AU2007236269A AU2007236269B2 AU 2007236269 B2 AU2007236269 B2 AU 2007236269B2 AU 2007236269 A AU2007236269 A AU 2007236269A AU 2007236269 A AU2007236269 A AU 2007236269A AU 2007236269 B2 AU2007236269 B2 AU 2007236269B2
Authority
AU
Australia
Prior art keywords
antibody
medicament
ccr2
treatment
monocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007236269A
Other languages
English (en)
Other versions
AU2007236269A1 (en
Inventor
Wolfgang Bruck
Matthias Mack
Alexander Mildner
Marco Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsmedizin Goettingen Georg August Universitaet
Universitätsklinikum Regensburg
Original Assignee
Georg August Univ Goettingen Stiftung Oeffentlichen Rechts
Universitaetsmedizin Goettingen Georg August Universitaet
Klinikum Rechts der Isar der Technischen Universitaet Muenchen
Universitätsklinikum Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Univ Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Goettingen Georg August Universitaet, Klinikum Rechts der Isar der Technischen Universitaet Muenchen, Universitätsklinikum Regensburg filed Critical Georg August Univ Goettingen Stiftung Oeffentlichen Rechts
Publication of AU2007236269A1 publication Critical patent/AU2007236269A1/en
Assigned to KLINIKUM DER UNIVERSITAET REGENSBURG - ANSTALT DES OEFFENTLICHEN RECHTS, Georg-August Universitat Gottingen Stiftung Offentlichen Rechts reassignment KLINIKUM DER UNIVERSITAET REGENSBURG - ANSTALT DES OEFFENTLICHEN RECHTS Amend patent request/document other than specification (104) Assignors: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, Klinikum der Universitat Regensburg - Anstalt des Offentlichen Rechts
Assigned to KLINIKUM DER UNIVERSITAET REGENSBURG - ANSTALT DES OEFFENTLICHEN RECHTS, GEORG-AUGUST-UNIVERSITAET GOETTINGEN STIFTUNG OEFFENTLICHEN RECHTS reassignment KLINIKUM DER UNIVERSITAET REGENSBURG - ANSTALT DES OEFFENTLICHEN RECHTS Amend patent request/document other than specification (104) Assignors: GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS, KLINIKUM DER UNIVERSITAET REGENSBURG - ANSTALT DES OEFFENTLICHEN RECHTS
Application granted granted Critical
Publication of AU2007236269B2 publication Critical patent/AU2007236269B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007236269A 2006-04-03 2007-04-02 Treatment of multiple sclerosis and/or rheumatoid arthritis Ceased AU2007236269B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
DE102006015341.3 2006-04-03
PCT/EP2007/002929 WO2007115713A1 (de) 2006-04-03 2007-04-02 Behandlung von multipler sklerose und/oder rheumatoider arthritis

Publications (2)

Publication Number Publication Date
AU2007236269A1 AU2007236269A1 (en) 2007-10-18
AU2007236269B2 true AU2007236269B2 (en) 2012-09-20

Family

ID=38226352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007236269A Ceased AU2007236269B2 (en) 2006-04-03 2007-04-02 Treatment of multiple sclerosis and/or rheumatoid arthritis

Country Status (8)

Country Link
US (1) US9068002B2 (https=)
EP (2) EP2004692B1 (https=)
JP (1) JP2009532399A (https=)
CN (1) CN101466735A (https=)
AU (1) AU2007236269B2 (https=)
CA (1) CA2648330C (https=)
DE (1) DE102006015341A1 (https=)
WO (1) WO2007115713A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276991C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
CN110709422B (zh) * 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
MX2024004447A (es) 2021-10-27 2024-05-08 Granite Bio Ag Anticuerpos dirigidos a ccr2.
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031949A1 (en) * 1996-03-01 1997-09-04 Consejo Superior De Investigaciones Cientificas Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2)
WO2000005265A2 (en) * 1998-07-23 2000-02-03 Millennium Pharmaceuticals, Inc. Anti-crr2 antibodies and methods of use therefor
WO2001057226A1 (en) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
SE0002045D0 (sv) 2000-05-31 2000-05-31 Sahltech Ab New use
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031949A1 (en) * 1996-03-01 1997-09-04 Consejo Superior De Investigaciones Cientificas Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2)
WO2000005265A2 (en) * 1998-07-23 2000-02-03 Millennium Pharmaceuticals, Inc. Anti-crr2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
WO2001057226A1 (en) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRUHEL et al. Journal of Immunology. 2004. 172(2): 890-898 *
SCHNEIDER et al. European Journal of Immunology. 2005. 35(3): 987-995 *

Also Published As

Publication number Publication date
US20090311273A1 (en) 2009-12-17
CA2648330A1 (en) 2007-10-18
JP2009532399A (ja) 2009-09-10
CA2648330C (en) 2015-11-24
CN101466735A (zh) 2009-06-24
EP2004692B1 (de) 2013-07-24
US9068002B2 (en) 2015-06-30
EP2481757A1 (de) 2012-08-01
WO2007115713A1 (de) 2007-10-18
EP2004692A1 (de) 2008-12-24
DE102006015341A1 (de) 2007-10-04
AU2007236269A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
Christensen et al. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis
JP7015820B2 (ja) 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
JP5693127B2 (ja) Ｎｋｇ２ｄの調節
Brühl et al. Targeting of Gr‐1+, CCR2+ monocytes in collagen‐induced arthritis
AU2007236269B2 (en) Treatment of multiple sclerosis and/or rheumatoid arthritis
JP2024026724A (ja) 抗ｃｘｃｒ２抗体及びその使用
JP2009543579A (ja) 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
JP2021508444A (ja) ＦｃＲｎに対する増大した親和性および少なくとも１つのＦｃフラグメント受容体に対する増大した親和性を有するＦｃフラグメントを伴う変異体
JP5777522B2 (ja) 初期段階の関節リウマチ治療用のｉｌ−３阻害剤
CN1261285A (zh) 治疗性蛋白抑制剂综合症的cd154阻断治疗
CN112451661A (zh) α-烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
US20080248025A1 (en) Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
TWI879859B (zh) 急性期之視神經脊髓炎之預防或治療劑
JP7576847B2 (ja) 免疫応答抑制剤
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
Soulillou et al. Monoclonal anti‐IL2‐receptor in organ transplantation
JP2022500387A (ja) Ｍｕｓｋ阻害
RU2820162C2 (ru) Варианты с fc-фрагментом, обладающие повышенной аффинностью к fcrn и повышенной аффинностью по меньшей мере к одному рецептору fc-фрагмента
DeVoss The role of classical allergy-related genes in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE APPLICANT NAME FROM KLINIKUM DER UNIVERSITAT REGENSBURG - ANSTALT DES OFFENTLICHEN RECHTS - AND GEORG-AUGUST- UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS TO KLINIKUM DER UNIVERSITAT REGENSBURG - ANSTALT DES OFFENTLICHEN RECHTS AND GEORG-AUGUST UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired